Clinical Trials Browser

relatlimab × Dermatologic × 30 days × Clear all

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT06743126 2026-04-13

SUPRAME

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

NCT05704933 2026-04-06

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Phase EARLY_PHASE1 Completed

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06295159 2026-04-01

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Phase 2 Recruiting

Melanoma

NCT07504796 2026-04-01

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

Phase 4 Not yet recruiting

Melanoma

NCT07281924 2026-03-24

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

Phase 1/2 Recruiting

Melanoma

NCT03521830 2026-03-20

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Basal Cell